BIO-Europe 2025: Herantis Pharma is developing HER-096 for Parkinson's, a blood-brain-barrier penetrant small peptide molecule that is designed to mimic the activity of CDNF
CEO Antti Vuolanto walks us through recent phase 1b data, which reported safety and PK data. Biomarker data will be forthcoming before the end of the year.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.